Nuvilex Inc. PMCB
- Market cap
- $4.9M
- P/E
- 0.0×
Follow PMCB
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.81 | 55.80 | 49.29 | 6.20 | 2.25 | 1.79 | 1.92 | 1.39 | 0.63 | 0.33 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| 237.15 | 162.75 | 106.95 | 94.55 | 57.35 | 3.10 | 3.23 | 2.58 | 1.90 | 1.05 |
High Price
|
|||
| 4 | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| (4) | (7) | (4) | (4) | (4) | (4) | (4) | 0 | 31 | (19) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| (4) | (7) | (4) | (4) | (4) | (4) | (4) | 0 | 31 | (19) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (7.51) | (10.07) | (5.28) | (4.23) | (2.45) | (0.27) | (0.22) | (1.80) | 3.19 | (2.77) |
Earnings/Sh
|
|||
| (5.64) | (7.49) | (3.74) | (2.59) | (2.30) | (0.27) | (0.19) | (0.22) | (0.41) | (0.61) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (5.64) | (7.49) | (3.74) | (2.59) | (2.30) | (0.27) | (0.19) | (0.22) | (0.41) | (0.61) |
Free CF/Sh
|
|||
| 13.67 | 8.51 | 6.54 | 5.63 | 4.61 | 5.79 | 3.73 | 2.89 | 7.08 | 3.97 |
Book Value/Sh
|
|||
| 1 | 1 | 1 | 1 | 1 | 16 | 19 | 10 | 7 | 8 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| (3) | (5) | (3) | (2) | (3) | (4) | (4) | (2) | (3) | (5) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| (3) | (5) | (3) | (2) | (3) | (4) | (4) | (2) | (3) | (5) |
FCF
|
|||
| 3 | 1 | 0 | 0 | 2 | 85 | 68 | 43 | 19 | 37 |
Working Cap'
|
|||
| — | — | — | 0 | 0 | — | — | — | 0 | — |
Total Debt
|
|||
| (3) | (1) | (1) | (1) | (2) | (85) | (68) | (50) | (16) | (37) |
Net Debt
|
|||
| 8 | 6 | 5 | 5 | 7 | 90 | 73 | 28 | 52 | 33 |
Sh' Equity
|
|||
| (56.15%) | (90.57%) | (66.70%) | (64.05%) | (52.34%) | (8.65%) | (5.27%) | (25.89%) | 40.60% | (45.54%) |
ROA
|
|||
| (60.05%) | (92.66%) | (56.65%) | (56.02%) | (50.01%) | (60.74%) | (86.76%) | 0.00% | (7.52%) | 0.00% |
ROIC
|
|||
| (60.83%) | (98.57%) | (75.26%) | (75.57%) | (60.35%) | (8.78%) | (5.31%) | (34.36%) | 58.74% | (54.48%) |
ROE
|
|||
Nuvilex Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | 0.0× | Compare |
| DRMA Dermata Therapeutics, Inc. | $4.7M | 0.0× | Compare |
| PCSA Heatwurx Inc. | $5.2M | 1.8× | Compare |
| ONCO Onconetix, Inc. | $4.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GRI GRI Bio, Inc. | $4.6M | 0.0× | Compare |
| ADTX Aditxt, Inc. | $4.4M | 0.0× | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $4.3M | 0.0× | Compare |
| LIMN Liminatus Pharma Inc. | $5.6M | 0.0× | Compare |
Nuvilex Inc. (PMCB) key facts
- Nuvilex Inc. (PMCB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, PMCB traded at $0.44, a market capitalization of $4.9 million.
- Return on equity was −54.5% and debt-to-equity 0.00.
Nuvilex Inc. (PMCB) Latest News
4 Dec
Nuvilex Inc. (PMCB) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. The company's recent developments and market movements have contributed to its increased visibility among investors. This trend may reflect broader market dynamics or specific company-related news that has captured attention. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
25 Nov
PharmaCyte Biotech has successfully monetized its stake in Femasys, enhancing its cash position and demonstrating effective strategic capital deployment. This move is expected to provide the company with additional financial resources to support its ongoing projects and initiatives. The monetization of the Femasys stake significantly strengthens PharmaCyte's financial position, which could impact its future strategic initiatives and investor sentiment.
Nuvilex Inc. (PMCB) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and interest among investors. The company's recent developments and market movements have contributed to its visibility, attracting attention from traders and analysts alike. This increased activity may indicate potential shifts in investor sentiment or market dynamics surrounding Nuvilex. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
20 Aug
PharmaCyte Biotech, Inc. has successfully closed a $7 million financing round, which is expected to support its ongoing clinical trials and operational activities. The financing is part of the company's strategy to advance its innovative therapies and enhance its market position. This funding will enable PharmaCyte to continue its development efforts and potentially accelerate its timelines for bringing new treatments to market. The $7 million financing is a significant boost that could enhance PharmaCyte's operational capabilities and accelerate its clinical development efforts.
18 Aug
PharmaCyte Biotech, Inc. has successfully raised $7 million in capital, led by existing investors. This funding is intended to support the company's ongoing development efforts and operational needs, enhancing its financial position as it advances its clinical programs. The capital raise may provide necessary funding for product development, but its overall impact on the company's long-term trajectory remains limited.
26 Feb
Nuvilex Inc. (PMCB) is highlighted as a penny stock to watch in February 2025 due to its recent advancements in biotechnology and potential market opportunities. The company is focusing on innovative treatments and has garnered attention for its strategic initiatives aimed at enhancing shareholder value. Analysts suggest that Nuvilex's developments could position it favorably within the competitive landscape, attracting investor interest. Recent advancements and strategic initiatives are likely to significantly impact Nuvilex's future performance and market positioning.
21 May
PharmaCyte Biotech invests $7 million in MyMD Pharmaceuticals, a biopharmaceutical company focused on inflammatory disease. The strategic investment in a clinical stage biopharmaceutical company with positive trial data is expected to significantly impact PharmaCyte's future collaborations and value creation.
15 Nov
PharmaCyte Biotech acquires $5 million stake in Femasys, Inc. The acquisition of a stake in an emerging women's health innovator is a significant strategic move that could impact Nuvilex Inc.'s future and market performance.
Femasys Inc. secures $6.85 million upfront investment from investors led by PharmaCyte Biotech, providing $23 million total cash runway into second half 2025. The strategic investment and partnership with PharmaCyte Biotech is expected to have a significant impact on Femasys' future commercialization efforts and product development.
31 Oct
PharmaCyte Biotech provides update on Cell-in-a-Box technology and plans to meet with FDA for guidance on further development. The potential FDA meeting and evaluation of additional opportunities could significantly impact PharmaCyte's future development and market performance.
15 Jun
PharmaCyte Biotech completed a tender offer to acquire shares of common stock, accepting 8,085,879 shares at $3.25 per share. The tender offer results will significantly impact PharmaCyte's financial position and potential strategic acquisitions.
11 May
PharmaCyte Biotech announces cash tender offer for up to 7,750,000 shares at $3.25 per share and completes $35 million financing of convertible preferred stock at $4.00 per share. The announcement of a cash tender offer and a significant private placement financing are expected to have a significant impact on Nuvilex Inc.'s future and market performance.